We are testing a new drug called DO-2 for patients with advanced or hard-to-treat solid tumors. The study aims to understand its safety and how the body processes it.
Health conditions and diseases that the clinical trial is designed to study and treat.
Locally advanced or metastatic non-small cell lung cancer (NSCLC) is a type of lung cancer that has spread beyond the lungs to nearby tissues or other parts of the body, making it difficult to treat. Symptoms may include persistent cough, chest pain, and difficulty breathing.
Advanced or refractory solid tumors refer to cancers that have progressed to an advanced stage or have not responded to standard treatments. Symptoms can vary widely depending on the tumor's location but may include pain, weight loss, and fatigue.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
